Associations between cigarette smoking status and colon cancer prognosis among participants in North Central Cancer Treatment Group Phase III Trial N0147

Journal of Clinical Oncology

Volumn 31, Issue 16, 2013, Pages 2016-2023

  Phipps, Amanda I ^a   Shi, Qian ^b   Newcomb, Polly A ^a   Nelson, Garth D ^b   Sargent, Daniel J ^b   Alberts, Steven R ^b   Limburg, Paul J ^b  

^a USA   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; K RAS PROTEIN; OXALIPLATIN; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; ONCOPROTEIN; PLATINUM COMPLEX; RAS PROTEIN;

ADJUVANT THERAPY; ADULT; ALCOHOL CONSUMPTION; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL OUTCOME; COLON ADENOCARCINOMA; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SMOKING; SMOKING CESSATION; TIME TO RECURRENCE; AGED; CANCER STAGING; COLON TUMOR; CONTROLLED CLINICAL TRIAL; GENETICS; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; MUTATION; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; QUESTIONNAIRE; RISK; RISK FACTOR; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLONIC NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; NEOPLASM STAGING; ODDS RATIO; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; QUESTIONNAIRES; RAS PROTEINS; RISK FACTORS; SMOKING; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 84880726087     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.46.2457     Document Type: Article

References (43)

1. Liang PS, Chen TY, Giovannucci E: Cigarette smoking and colorectal cancer incidence and mortality: Systematic review and meta-analysis. Int J Cancer 124:2406-2415, 2009
2. Botteri E, Iodice S, Bagnardi V, et al: Smoking and colorectal cancer: A meta-analysis. JAMA 300: 2765-2778, 2008
3. Limsui D, Vierkant RA, Tillmans LS, et al: Cigarette smoking and colorectal cancer risk by molecularly defined subtypes. J Natl Cancer Inst 102:1012-1022, 2010
4. Slattery ML, Curtin K, Anderson K, et al: Associations between cigarette smoking, lifestyle factors, and microsatellite instability in colon tumors. J Natl Cancer Inst 92:1831-1836, 2000
5. Diergaarde B, Vrieling A, van Kraats AA, et al: Cigarette smoking and genetic alterations in sporadic colon carcinomas. Carcinogenesis 24:565-571, 2003
6. Chia VM, Newcomb PA, Bigler J, et al: Risk of microsatellite-unstable colorectal cancer is associated jointly with smoking and nonsteroidal anti-inflammatory drug use. Cancer Res 66:6877-6883, 2006
7. Yang P, Cunningham JM, Halling KC, et al: Higher risk of mismatch repair-deficient colorectal cancer in alpha(1)-antitrypsin deficiency carriers and cigarette smokers. Mol Genet Metab 71:639-645, 2000
8. Samowitz WS, Albertsen H, Sweeney C, et al: Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer. J Natl Cancer Inst 98:1731-1738, 2006
9. McCleary NJ, Niedzwiecki D, Hollis D, et al: Impact of smoking on patients with stage III colon cancer: Results from Cancer and Leukemia Group B 89803. Cancer 116:957-966, 2010
10. Nickelsen TN, Jørgensen T, Kronborg O: Lifestyle and 30-day complications to surgery for colorectal cancer. Acta Oncol 44:218-223, 2005
11. Richards CH, Platt JJ, Anderson JH, et al: The impact of perioperative risk, tumor pathology and surgical complications on disease recurrence following potentially curative resection of colorectal cancer. Ann Surg 254:83-89, 2011
12. Munro AJ, Bentley AH, Ackland C, et al: Smoking compromises cause-specific survival in patients with operable colorectal cancer. Clin Oncol (R Coll Radiol) 18:436-440, 2006
13. Phipps AI, Baron J, Newcomb PA: Prediag-nostic smoking history, alcohol consumption, and colorectal cancer survival: The Seattle Colon Cancer Family Registry. Cancer 117:4948-4957, 2011
14. Alberts SR, Sargent DJ, Nair S, et al: Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: A randomized trial. JAMA 307:1383-1393, 2012
15. Bokemeyer C, Bondarenko I, Makhson A, et al: Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27:663-671, 2009
16. Domingo E, Laiho P, Ollikainen M, et al: BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. J Med Genet 41: 664-668, 2004
17. Lindor NM, Burgart LJ, Leontovich O, et al: Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol 20:1043-1048, 2002
18. Kruskal WH, Wallis WA: Use of ranks in one-criterion variance analysis. J Am Stat Assoc 47:583-621, 1952
19. Fleiss JL: Statistical Methods for Rates and Proportions (ed 2). New York, NY, John Wiley & Sons, 1981
20. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
21. Hosmer DW Jr, Lemeshow S: Applied Survival Analysis: Regression Modeling for Time to Event Data. New York, NY, John Wiley & Sons, 1999
22. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-220, 1972
23. Therneau TM, Grambsch PM: Modeling Survival Data: Extending the Cox Model. New York, NY, Springer, 2000
24. Yu GP, Ostroff JS, Zhang ZF, et al: Smoking history and cancer patient survival: A hospital cancer registry study. Cancer Detect Prev 21:497-509, 1997
25. Park SM, Lim MK, Shin SA, et al: Impact of prediagnosis smoking, alcohol, obesity, and insulin resistance on survival in male cancer patients: National Health Insurance Corporation Study. J Clin Oncol 24:5017-5024, 2006
26. French AJ, Sargent DJ, Burgart LJ, et al: Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. Clin Cancer Res 14:3408-3415, 2008
27. Fariña-Sarasqueta A, van Lijnschoten G, Moerland E, et al: The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. Ann Oncol 21:2396-2402, 2010
28. Kalady MF, Dejulius KL, Sanchez JA, et al: BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis. Dis Colon Rectum 55:128-133, 2012
29. Ogino S, Shima K, Meyerhardt JA, et al: Predictive and prognostic roles of BRAF mutation in stage III colon cancer: Results from intergroup trial CALGB 89803. Clin Cancer Res 18:890-900, 2012
30. Ogino S, Nosho K, Kirkner GJ, et al: CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 58:90-96, 2009
31. Boland CR, Thibodeau SN, Hamilton SR, et al: A National Cancer Institute Workshop on Microsat-ellite Instability for cancer detection and familial predisposition: Development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58:5248-5257, 1998
32. Samowitz WS, Sweeney C, Herrick J, et al: Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 65:6063-6069, 2005
33. Samadder NJ, Vierkant RA, Tillmans LS, et al: Cigarette smoking and colorectal cancer risk by KRAS mutation status among older women. Am J Gastroenterol 107:782-789, 2012
34. Weijenberg MP, Aardening PW, de Kok TM, et al: Cigarette smoking and KRAS oncogene mutations in sporadic colorectal cancer: Results from the Netherlands Cohort Study. Mutat Res 652:54-64, 2008
35. Belinsky SA, Palmisano WA, Gilliland FD, et al: Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res 62:2370-2377, 2002
36. Soria JC, Rodriguez M, Liu DD, et al: Aberrant promoter methylation of multiple genes in bronchial brush samples from former cigarette smokers. Cancer Res 62:351-355, 2002
37. Kane MF, Loda M, Gaida GM, et al: Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res 57:808-811, 1997
38. Hecht SS: Lung carcinogenesis by tobacco smoke. Int J Cancer 131:2724-2732, 2012
39. Cucina A, Dinicola S, Coluccia P, et al: Nicotine stimulates proliferation and inhibits apoptosis in colon cancer cell lines through activation of survival pathways. J Surg Res 178:233-241, 2012
40. Land SR: Methodologic barriers to addressing critical questions about tobacco and cancer prognosis. J Clin Oncol 30:2030-2032, 2012
41. Slattery ML, Curtin K, Sweeney C, et al: Diet and lifestyle factor associations with CpG island methylator phenotype and BRAF mutations in colon cancer. Int J Cancer 120:656-663, 2007
42. Nash GM, Gimbel M, Cohen AM, et al: KRAS mutation and microsatellite instability: Two genetic markers of early tumor development that influence the prognosis of colorectal cancer. Ann Surg Oncol 17:416-424, 2010
43. Ganz PA: Host factors, behaviors, and clinical trials: Opportunities and challenges. J Clin Oncol 30:2817-2819, 2012